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The role of volume contraction in the hypocalciuric action of
chlorothiazide. Thiazide-induced hypocalciuria usually requires
two to four days of drug treatment for its full expression. The
present experiments were designed to test the possibility that an
immediate hypocalciuria could be produced in subjects whose
extracellular volumes were already contracted. In previously un-
treated subjects, chlorothiazide (2 g/day) did not produce hypocal-
ciuria on the first day of treatment. Hypocalciuria occurred on the
second day and was somewhat enhanced on the third and fourth
days of treatment. In subjects pretreated with furosemide (40 mg
two or three times a day for two days), chlorothiazide produced
hypocalciuria on the first day of its use. Under the influence of
chlorothiazide, there was a strong, linear correlation between the
changes in the excretion of calcium and sodium. The results are
consistent with the idea that chlorothiazide enhances the ratio of
calcium to sodium reabsorptions and that this tendency for abso-
lute hypocalciuria can be overridden by a large natriuretic response
to the drug. Volume contraction, which minimizes the natriuretic
response to diuretics, allows a more immediate and pronounced
hypocalciuric response to thiazides.
Le réle de Ia contraction des liquides extra-cellulaires dans Ia
diminution de Ia calciurie par Ic clilorothiazide. L'hypocalciurie
induite par les thiazides n'atteint son expression complete qu'après
deux a quatre jours de traitement. Les experiences rapportées ont
été réalisées pour évaluer Ia possibilité d'obtention d'une hypocal-
ciurie immediate chez les sujets dont le volume extracellulaire est
diminué des le depart. Chez des sujetsno préalablement traitées,
Ic chlorothiazide (2 g/jour) n'a pas déterminé d'hypocalciurie le
premier jour de l'administration. Elle est survenue le second jour et
a été renforcée les troisiCme et quatrieme jours. Chez des sujets
prCtraites par Ia furosémide (40 mg deux ou trois fois par jour
pendant deux jours) Ic chlorothiazide produit une hypocalciurie
des le premier jour de son administration. Sous l'influence du
chlorothiazide existe une forte correlation linéaire entre les modifi-
cations des excretions du calcium et du sodium. Les résultats sont
compatibles avec l'hypothèse suivant laquelle Ic chlorothiazide
augmente Ia proportion de calcium réabsorbée par rapport au
sodium et que cette tendance vers l'hypocalciurie absolue peut être
annulée par une reponse natriurétique importante au thiazide. La
contraction du volume extra-cellulaire, qui diminue Ia réponse
natriurétique aux diurCtiques, permet une hypocalciurie plus pré-
coce et plus importante en réponse aux thiazides.
Thiazides and related diuretics induce hypocal-
ciuria, the basis for their use in the prophylaxis of
Received for publication February 4, 1976; and in revised form
March 29, 1976.
° 1976, by the International Society of Nephrology.
164
recurrent urolithiasis [1, 2]. In clinical use the full
hypocalciuric effect is not seen on the first day of drug
administration; it is achieved after one to three days
of continued use [2—4]. This latent period is among
factors suggesting that the action is a consequence of
drug-induced contraction of the extracellular fluid
volume [5], an interpretation supported by experi-
ments in which hypocalciuria was prevented by re-
placement of thiazide-induced salt losses [3, 6]. How-
ever, extracellular volume contraction per se is not
sufficient to account for the effect. Comparable vol-
ume contraction produced during chronic use of fu-
rosemide does not result in hypocalciuria [3].
Thiazides also exert hypocalciuric actions in exper-
imental animals [7—10]. When sodium excretion is
initially high, injected chiorothiazide (CTZ) elicits an
immediate hypocalciuria through a direct action on
the kidneys [8, 10]. It has been suggested that the
acute hypocalciuria observed in animals and the
chronic effect seen in man are manifestations of the
same direct renal action [10]. The failure to observe
the acute hypocalciuria in humans and in experimen-
tal animals with initially low rates of sodium excre-
tion has been attributed to the proportionately great,
drug-induced increment in sodium excretion in such a
setting [10, 11]. Sodium and calcium excretion rates
vary in parallel in a variety of conditions [8] and it is
conceivable that a large increment in sodium excre-
tion induced by a drug may mask its inherent ability
to produce an acute, absolute hypocalciuria. This
formulation is supported by the observation that cal-
cium excretion, even when initially enhanced by
thiazide treatment, does not usually achieve the level
seen at comparable rates of sodium excretion pro-
duced by other means [11]. Accordingly, at usual
rates of sodium turnover both the direct renal action
of thiazides (calcium-retaining action) and volume
contraction (which minimizes drug-induced natriur-
esis with its attendant calciuretic tendency) are neces-
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sary for absolute hypocalciuria; neither by itself is
sufficient. Were this hypothesis correct, it should be
possible to demonstrate absolute hypocalciuria on
the first day of thiazide administration in subjects
with already contracted extracellular fluid volume.
This paper describes this phenomenon in subjects
pretreated with furosemide.
Methods
The 12 subjects were male and female medical stu-
dents, graduate students or laboratory personnel.
They had no known diseases, ranged in age from 20
to 27 yr and in weight from 54 to 77 kg. Twenty
experiments were performed, 12 of which (two
groups of six) will be reported in detail. The experi-
mental procedure was in large part patterned after
that employed by Brick man, Massry and Coburn [3].
Each subject was asked to describe a typical day's
food intake and was then instructed to purchase a
nine-day supply of that food and to eat the same
quantities of the same foods at the same intervals for
nine successive days. No samples were taken on the
first two days of the diet. On the third day, first day of
the experiment, and subsequent days a venous blood
sample was drawn at 8 AM and 24-hr collections of
urine, 8 AM to 8 AM, were made. The subjects main-
tained their normal activities throughout the study.
Several subjects were studied on more than one occa-
sion but no subject participated more than once in
any one treatment group.
Group C. After three days of sample collections,
the subjects were given I g of chlorothiazide by
mouth twice daily, 8 AM and 8 PM, for the remainder
of the experiments. Two subjects from group C were
restudied with the same procedure except that hydro-
chlorothiazide, 100 mg twice a day, was used in-
stead of chiorothiazide. The experiments with hydro-
chiorothiazide were not included in calculating the
means for the group.
Group F-C. After three days of sample collections,
the subjects were given 40 mg of furosemide by
mouth three times a day, 8 AM, 4 PM and midnight for
two days, and chlorothiazide, as above, for the final
two days of the experiment.
Furosemide-CTZ. A third group of six subjects was
studied using a protocol identical to F-C except that
furosemide, 40 mg, was administered only twice
daily, 8 AM and 8 PM. The results of this group were
similar to those in group F-C and are included only in
the final summary (Fig. 6).
Urine and plasma samples were analyzed for
creatinine with an autoanalyzer method, sodium and
potassium by flame photometry and calcium by
Table 1. Summary of control observationsa
Group C Group F-C
Weight, kg(range)
Ccr, mI/mm
Na excretion, mEq/day
Caexcretion,mEq/day
K excretion, mEq/day
PN,mEq/Iiter
Pea, mEq/liier
PK,mEq/liter
55-73
96.7 1.8
95.2 + 8.2
6.75 + 0.44
55.3 5.4
139 + 2.4
4.76 0.06
4.00 0.11
55-77
106.9
110.0 +
6.21
67.4 +
136
4.75 +
4.11
8.7
10.3
1.25
8.4
1.0
0.06
0.11
Except for body weights, the data are means SFM.
atomic absorption spectroscopy. Chlorothiazide in
urine was determined by a colorimetric method [12].
The data on creatinine clearance, electrolyte excre-
tion and electrolyte concentrations in plasma are pre-
sented as follows. The value for a given plasma con-
stituent on each experimental day was taken to be the
mean of the 8 AM values at the start and end of the
urine collection period. For each subject mean values
for the various factors were calculated from the sam-
ples obtained on the three control (pre-drug) days.
These means were treated as single values in calcu-
lating the mean control values for a group (Table I).
The data from each day's samples (including control
days) were expressed as percentages of the control
mean for each subject. The results for each group are
given in the figures as means of such percentages.
Student's t test (paired comparison) was used within
each group to test whether the mean difference in
calcium excretion (mEq/day), mean control minus
first day of chlorothiazide administration, was signifi-
cantly different from zero. Regression lines were cal-
culated by the method of least squares.
Results
Table 1 contains the mean pre-drug values for
creatinine clearance (Ccr) and the excretion rates and
plasma concentrations of sodium (PNa), calcium
(Pca) and potassium (PK) for groups C and F-C.
During the administration of the diuretics (days 4 to
7), there were minor decreases in plasma sodium
concentrations, very small increments in P, appre-
ciable declines in PK (Fig. 1) and small decreases in
Ccr (Fig. 2). The results from the two groups were
generally comparable.
In group C on the first day of CTZ administration,
there was an increase in sodium excretion to about
2.5 times the control values (Fig. 2). The natriuretic
effect of CTZ waned on subsequent days of adminis-
tration, sodium excretion falling to 64% of control on
the fourth drug day (day 7 in the figure). The in-
crements in sodium excretion during the two days of
furosemide administration in group F-C were similar
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to those seen in group C with CTZ administration. In300
group F-C on the third drug day when CTZ was
o Group C substituted for furosemide, sodium excretion re-250 • Group F-C mained above control levels in contrast to the third* First CTZ day
drug day in group C, when sodium excretion wasC
.2 200 slightly below control. Thus, pretreatment with fu-
rosemide greatly diminished but did not completelyxa
eliminate the initial natriuretic response to CTZ. On150
the fourth drug day (day 7 in the figure), sodium
100 4
excretion in group F-C fell to below control levels.
Potassium excretion was elevated above control 1ev-
bothgroups(Fig. 2).
The patterns of calcium excretion are displayed in
200 Fig. 3. On the first day of CTZ administration, in
group C calcium excretion increased in every subject.
However, the increments were quite variable, ranging
.2 150
4 4 from 0.05 to 4,4 mEq/day (0.7 to 78% above control),
x and the mean increment for the group was not statis-100 tically significant (0.1 > P> 0.05). On subsequent
days CTZ elicited absolute hypocalciuria. In group
sc F-C there was the expected increment in calcium1 2 3 4 5 6 7
excretion on the two days of furosemide administra-Day tion. In contrast to the subjects in group C, eachFig. 2. The clearances of creatinine and the daily excretions of
sodium and potassium in groups C and F-C, expressed as percent of subject in group F-C decreased calcium excretion on
control, the first day of CTZ administration (day 6 in the
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Fig. 4. The daily excretion of chlorothiazide in groups C and F-C.
figure). The mean of calcium excretion in group F-C
on day 6 was 3.56 0.85 mEq. The mean difference
from the pre-drug values (Table 1) is significantly
different from zero (P < 0.02).
Two of the subjects in group C were restudied
using hydrochlorothiazide, 100 mg twice a day, in-
stead of CTZ. In each case the results were in-
distinguishable from those of the corresponding CTZ
experiment. A series of six experiments was per-
formed using essentially the same protocol as in
group F-C except that furosemide, 40 mg, was given
only twice per day. The results were qualitatively
similar; an absolute hypocalciuria occurred on the
first day of CTZ administration. However, the effect
was not as great as in group F-C. Calcium excretion
fell to 80 5% of control (P < 0.02) on the first day
of CTZ administration and declined to 72 7% on
the second day.
The daily excretion (presumably absorption) of
CTZ was quite variable among subjects. The lowest
single value for 24-hr excretion was 88 mg (4.4% of
the ingested dose); the highest was 468 mg (23.4% of
the ingested dose). On average, between 10 and 13%
of the daily dose was excreted in 24 hr, there being no
significant trends with time or differences between
groups (Fig. 4). Despite the marked variation among
subjects, drug excretion for each subject was quite
consistent. In the course of these studies, some of the
subjects were observed on more than one occasion.
As displayed in Fig. 5, there is a strong correlation
between CTZ excretion on one occasion as compared
to another.
Discussion
The general patterns of response to the diuretics
observed here, including some of the effects on cal-
cium, are consistent with the findings of Brickman et
al [3] and Parfitt [4]. The latter authors have dis-
cussed these patterns and the related literature exten-
sively; consequently, we will confine our remarks
largely to the new findings.
In dogs and man the relationship between sodium
and calcium excretions is linear over a wide range of
sodium excretion induced by saline infusion or
changes in dietary sodium [13, 14]. Several factors
either do not seriously disturb this relationship or
somewhat enhance calcium excretion relative to so-
dium excretion. Among these factors are hemody-
namic changes [15, 16], mercurial diuretics [8, 11,
17—20], furosemide [10, 20, 21—27], ethacrynic acid
[23, 24, 28], and the osmotic diuretic, mannitol [10,
11, 19]. The actions of thiazides contrast with the
foregoing. On initial administration they may en-
hance, diminish or not change the rate of calcium
excretion [3, 4, 8—10, 21, 26, 27, 29—32]; on chronic
administrtion they diminish calcium excretion [1, 3,
4, 9, 3 2—34]. It seems likely that these various respon-
ses to thiazides are the result of changes in "a balance
between two opposing factors—an increase (in cal-
cium excretion) in some way related to the increase in
sodium excretion, and a decrease as a result of some
intrinsic action of the drug" [II].
It has been established in acute experiments in
humans and dogs that under the influence of chloro-
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Fig. 6. The relation between the changes in calcium and sodium
excretion rates in the various groups on days w1en chiorothiazide was
given. Points a, b, c and d correspond to days 4 through 7, respec-
tively, for group C. Points e and f correspond to days 6 and 7,
respectively, for group F-C. Points g and h are from the corre-
sponding days for the other CTZ-furosemide group. y = 0.39x +
5.6; r = 0.96. The inset repeats the regression line from the main
part of the figure. The solid symbols represent the mean values for
each of the two days of furosemide pretreatment in the two groups
which were subsequently treated with CTZ.
thiazide the relationship between sodium and calcium
excretion remains linear but the slope of the relation-
ship is changed such that at any level of sodium
excretion the excretion of calcium is less than normal
[10, 11, 27, 35, 36]. Figure 6 contains the mean data
for each drug day from the three groups of subjects in
this study. It is seen in the main body of the figure
that under the influence of chlorothiazide there is a
definite, linear relationship between the change in
sodium excretion and the change in calcium excre-
tion. Note that the figure contains results from the
first day of CTZ administration as well as from sub-
sequent days; i.e., the acute and chronic results seem
to be parts of a single relationship between the excre-
tions of the two ions. Presumably, that single rela-
tionship is the manifestation of the "intrinsic action
of the drug", an action which is compatible with
either an increase in calcium excretion or hypocal-
ciuria depending on the extent of change in sodium
excretion. This analysis defines the role of volume
depletion as being mediated through its limiting the
natriuretic response to the drug. The point designated
a represents the first day of CTZ treatment in group
C; the small hypercalciuria is associated with a sub-
stantial natriuresis. On the second day of CTZ treat-
ment (point b), the lesser natriuresis allows the hypo-
calciuric action of the drug to be manifest. On the
other hand, in group F-C, CTZ did not elicit a large
initial natriuretic effect because of pretreatment with
furosemide and thus the hypocalciuric action was
immediately manifest (point e). In the other furose-
mide-CTZ group, the natriuresis on the first day of
CTZ administration was somewhat greater than in
group F-C and the initial hypocalciuria was less pro-
nounced (point g). The inset to Fig. 6 demonstrates
that the data obtained during furosemide administra-
tion fell well above the regression line for the rela-
tionship covered with CTZ treatment.
It is necessary to consider the possibility that part
of the hypocalciuria observed on day 6 in group F-C
is the result of prior treatment with furosemide per Se,
rather than a consequence of CTZ administration.
Brickman et al [3] observed a small (17%) and not
statistically significant decline in calcium excretion on
the day following a four-day course of furosemide.
This small decline in calcium excretion was accom-
panied by a fall in sodium excretion (69%) and was
probably a reflection of the normal tendency of so-
dium and calcium excretions to change in the same
direction. In contrast, in group F-C sodium excretion
did not fall below pre-drug levels on day 6 while
calcium excretion fell by 45%. The cumulative in-
crement in urinary calcium loss produced by furose-
mide administration averaged 12.4 mEq in the study
of Brickman et al and 10.3 mEq in group F-C. Con-
sequently, we believe that the hypocalciuria in group
F-C was largely if not entirely attributable to admin-
istration of CTZ.
The demonstration of an immediate onset of hypo-
calciuria under the appropriate conditions in man is
consistent with the suggestion that the acute hypocal-
ciuric response to CTZ in dogs and the chronic re-
sponse in man are manifestations of the same renal
action of the drug. There remains, however, one fac-
tor which is unresolved. The acute hypocalciuric re-
sponse to CTZ in dogs [10], the acute dissociation of
sodium and calcium excretion in man [37] and the
chronic hypocalciuric action in rats [9] all seem to be
independent of parathyroid hormone, However, the
chronic hypocalciuric action of thiazides has not been
observed in humans with hypoparathyroidism [3, 4].
The reason for this is obscure.
There are as yet no micropuncture experiments
which demonstrate an absolute enhancement by a
thiazide of calcium reabsorption in any nephron seg-
ment. Such a phenomenon must occur to account for
thiazide-induced hypocalciuria. It is known, how-
ever, that normally the reabsorptions of calcium and
sodium are approximately proportional throughout
the nephron [e. g., 27, 35, 38] and that the dis-
sociation of those reabsorptions by thiazides as well
as their major saluretic action occurs in the distal
convoluted tubule [27, 35, 39]. On that basis, the fol-
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lowing seems to be a plausible interpretation of the
present results. Volume depletion by limiting the de-
livery of sodium to the distal tubule [40, 41] would re-
sult in a diminished natriuretic response to thiazides.
One anticipates that volume depletion would also
limit the load of calcium entering the distal tubule.
Those factors in addition to the intrinsic ability of
thiazides to enhance distal calcium reabsorption rela-
tive to that of sodium would result in hypocalciuria.
The regression analysis (Fig. 6) suggests that when
a steady state is achieved during chronic CTZ admin-
istration (when sodium excretion equals intake), cal-
cium excretion would be 55% of normal. However,
we suspect that the effect observed in this study was
not maximal for the following reasons. 1) In man the
i.v. administration of CTZ (1.5 g) caused a greater
dissociation of sodium and calcium excretions than
did oral administration of 2 g (the daily dose in these
studies) [Ii]. The difference is probably attributable
to the incomplete absorption of CTZ from the gas-
trointestinal tract. 2) In dogs the action on calcium
excretion was correlated with the concentration of
CTZ in urine and the maximal action occurred in
urinary CTZ concentrations in excess of 700 tg/ml
[10]. In the present work the concentrations in urine
were much lower, ranging from 37 to 320 tg/ml in
the various 24-hr collections. We could detect only a
suggestion of greater effects at greater drug concen-
trations, which was not statistically significant. The
inherent variability in the subjects, the fact that CTZ
concentrations must have fluctuated during the day
and the small number of experiments may have pre-
cluded a rigorous demonstration. 3) The maximal
effect of CTZ on the calcium-sodium relationship in
the dog [10] was considerably greater than that ob-
served in this study.
It is probable that the excretion of CTZ provided a
reasonable index of its absorption from the gastroin-
testinal tract. Although there is some enterohepatic
circulation of chlorothiazide [12], an injected dose is
completely recovered in urine within 24 hr [42]. The
fractional recovery of CTZ in urine in this study is
consistent with the results of Young, Forrester and
Morgan [43], but was on average lower than that
reported by Brettell, Aikawa and Gordon [42]. The
disparity between the latter studies may in part be a
reflection of the small numbers of subjects involved
and the marked suject-to-subject variation described
herein. With the dose employed in this study, the
variation in absorption appears to have little impact
on natriuresis; there was no correlation between ex-
tent of natriuresis and the urinary recovery of the
drug. This factor might become important with
smaller doses.
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